Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
EZH2 mutation
i
Other names:
EZH2, ENX-1, EZH1, KMT6, KMT6A, Enhancer of zeste 2 polycomb repressive complex 2 subunit
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2146
Related biomarkers:
Expression
Mutation
CNA
Others
‹
EZH2 overexpression (2)
EZH2 underexpression (2)
EZH2 positive (1)
EZH2 overexpression (2)
EZH2 underexpression (2)
EZH2 positive (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
EZH2 mutation
Follicular Lymphoma
EZH2 mutation
Follicular Lymphoma
tazemetostat
Sensitive: A1 - Approval
tazemetostat
Sensitive
:
A1
tazemetostat
Sensitive: A1 - Approval
tazemetostat
Sensitive
:
A1
EZH2 mutation
Acute Myelogenous Leukemia
EZH2 mutation
Acute Myelogenous Leukemia
azacitidine
Sensitive: B - Late Trials
azacitidine
Sensitive
:
B
azacitidine
Sensitive: B - Late Trials
azacitidine
Sensitive
:
B
EZH2 mutation
Diffuse Large B Cell Lymphoma
EZH2 mutation
Diffuse Large B Cell Lymphoma
tazemetostat
Sensitive: C1 - Off-label
tazemetostat
Sensitive
:
C1
tazemetostat
Sensitive: C1 - Off-label
tazemetostat
Sensitive
:
C1
EZH2 mutation
Follicular Lymphoma
EZH2 mutation
Follicular Lymphoma
valemetostat
Sensitive: C2 – Inclusion Criteria
valemetostat
Sensitive
:
C2
valemetostat
Sensitive: C2 – Inclusion Criteria
valemetostat
Sensitive
:
C2
EZH2 mutation
Follicular Lymphoma
EZH2 mutation
Follicular Lymphoma
rituximab
Resistant: C3 – Early Trials
rituximab
Resistant
:
C3
rituximab
Resistant: C3 – Early Trials
rituximab
Resistant
:
C3
EZH2 mutation
Myelodysplastic Syndrome
EZH2 mutation
Myelodysplastic Syndrome
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
EZH2 mutation
Diffuse Large B Cell Lymphoma
EZH2 mutation
Diffuse Large B Cell Lymphoma
CPI-169
Sensitive: D – Preclinical
CPI-169
Sensitive
:
D
CPI-169
Sensitive: D – Preclinical
CPI-169
Sensitive
:
D
EZH2 mutation
Diffuse Large B Cell Lymphoma
EZH2 mutation
Diffuse Large B Cell Lymphoma
CPI-169 + CPI-203
Sensitive: D – Preclinical
CPI-169 + CPI-203
Sensitive
:
D
CPI-169 + CPI-203
Sensitive: D – Preclinical
CPI-169 + CPI-203
Sensitive
:
D
EZH2 mutation
Follicular Lymphoma
EZH2 mutation
Follicular Lymphoma
CPI-169
Sensitive: D – Preclinical
CPI-169
Sensitive
:
D
CPI-169
Sensitive: D – Preclinical
CPI-169
Sensitive
:
D
EZH2 mutation
Lymphoma
EZH2 mutation
Lymphoma
EED inhibitor
Sensitive: D – Preclinical
EED inhibitor
Sensitive
:
D
EED inhibitor
Sensitive: D – Preclinical
EED inhibitor
Sensitive
:
D
EZH2 mutation
Diffuse Large B Cell Lymphoma
EZH2 mutation
Diffuse Large B Cell Lymphoma
SHR-2554
Sensitive: D – Preclinical
SHR-2554
Sensitive
:
D
SHR-2554
Sensitive: D – Preclinical
SHR-2554
Sensitive
:
D
EZH2 mutation
Diffuse Large B Cell Lymphoma
EZH2 mutation
Diffuse Large B Cell Lymphoma
chidamide + SHR-2554
Sensitive: D – Preclinical
chidamide + SHR-2554
Sensitive
:
D
chidamide + SHR-2554
Sensitive: D – Preclinical
chidamide + SHR-2554
Sensitive
:
D
EZH2 mutation
Diffuse Large B Cell Lymphoma
EZH2 mutation
Diffuse Large B Cell Lymphoma
USP47 inhibitor
Sensitive: D – Preclinical
USP47 inhibitor
Sensitive
:
D
USP47 inhibitor
Sensitive: D – Preclinical
USP47 inhibitor
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login